Metabolic Dysfunction-Associated Steatohepatitis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of NASH for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s NASH forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with NASH?
• Of all people with NASH, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all those people formally diagnosed with NASH, what is their liver fibrosis stage?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NASH over the forecast period?

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following NASH subpopulations:

• Advanced fibrosis status.
• Obesity status.
• Diagnosis status.
  • Diabetes status.
  • Fibrosis stage (F0-F4).
  • Treatment status.

Note: Coverage may vary by country.